Avivagen Inc

Chart & Performance

D1W1MN

P/E

—

P/S

0.01

EPS

—

Div Yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

39.52%

Revenues

939k

-27.53%

Net income

-6m

L-5.13%

CFO

-3m

L-32.24%

Profile

Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

URL

https://avivagen.com/

IPO date

Mar 04, 2004

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CAD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY
Title CAD in thousands, except ratios and share amounts	2022‑10	2021‑10	2020‑10	2019‑10	2018‑10	2017‑10	2016‑10	2015‑10
Income
Revenues	939 -27.53%
Cost of revenue	2,436
Unusual Expense (Income)
NOPBT	(1,497)
NOPBT Margin
Operating Taxes	1,769
Tax Rate
NOPAT	(3,265)
Net income	(6,066) -5.13%
Dividends
Dividend yield
Proceeds from repurchase of equity	4,029
BB yield
Debt
Debt current	835
Long-term debt	5,276
Deferred revenue
Other long-term liabilities
Net debt	5,820
Cash flow
Cash from operating activities	(3,117)
CAPEX
Cash from investing activities
Cash from financing activities	1,999
FCF	(1,729)
Balance
Cash	290
Long term investments
Excess cash	243
Stockholders' equity	(10,299)
Invested Capital	10,112
ROIC
ROCE	798.84%
EV
Common stock shares outstanding	66,028
Price
Market cap
EV
EBITDA	(1,409)
EV/EBITDA
Interest	1,769
Interest/NOPBT